Breaking Finance News

Optibiotix Health Plc (LON:OPTI) has been reiterated to Corporate in a statement by finnCap earlier today.

Having a price of 71.00GBX, Optibiotix Health Plc (LON:OPTI) traded -3.14% lower on the day. With the last stock price up -1.69% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Optibiotix Health Plc has recorded a 50-day average of 67.17GBX and a two hundred day average of 70.69GBX. Volume of trade was down over the average, with 3,400 shares of OPTI changing hands under the typical 217,068

finnCap has reiterated Optibiotix Health Plc (LON:OPTI) to Corporate in a statement released on 9/13/2017.

Performance Chart

Optibiotix Health Plc (LON:OPTI)

With a market cap of 0 GBX, Optibiotix Health Plc has 52 week low of 59.00GBX and a 52 week high of 90.00GBX .

General Information About Optibiotix Health Plc (LON:OPTI)

Optibiotix Health Plc is a life sciences company developing a range of products to modify the human microbiome. The Company's principal activity is research and development into microbiome modulators. It operates in UK segment. The Company has a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is operated by its OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact on human physiology. Its Optiscreen is a screening and optimization technology platform designed to identify microbes within the human microbiome with metabolic pathways, which can interact with human physiological processes. Its OptiBiotic is a platform technology, which generates compounds and screens them for their ability to modulate the human microbiome and its microbial end products. Its platforms are applicable across a range of other human diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *